Global burden of hepatitis B virus: current status, missed opportunities and a call for action (original) (raw)

• Yuen, M. F. et al. Hepatitis B virus infection. Nat. Rev. Dis. Primers 4, 18035 (2018).
  PubMed Google Scholar
• Iannacone, M. & Guidotti, L. G. Immunobiology and pathogenesis of hepatitis B virus infection. Nat. Rev. Immunol. 22, 19–32 (2022).
  CAS PubMed Google Scholar
• Sung, W. K. et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 44, 765–769 (2012).
  CAS PubMed Google Scholar
• Tu, T., Budzinska, M. A., Vondran, F. W. R., Shackel, N. A. & Urban, S. Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles. J. Virol. https://doi.org/10.1128/JVI.02007-17 (2018).
  Article PubMed PubMed Central Google Scholar
• Shiffman, M. L. Management of acute hepatitis B. Clin. Liver Dis. 14, 75–91 (2010).
  PubMed Google Scholar
• Hyams, K. C. Risks of chronicity following acute hepatitis B virus infection: a review. Clin. Infect. Dis. 20, 992–1000 (1995).
  CAS PubMed Google Scholar
• Tong, S. & Revill, P. Overview of hepatitis B viral replication and genetic variability. J. Hepatol. 64, S4–S16 (2016).
  CAS PubMed PubMed Central Google Scholar
• Hsu, Y. S. et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35, 1522–1527 (2002).
  PubMed Google Scholar
• Nguyen, L. H., Chao, D., Lim, J. K., Ayoub, W. & Nguyen, M. H. Histologic changes in liver tissue from patients with chronic hepatitis B and minimal increases in levels of alanine aminotransferase: a meta-analysis and systematic review. Clin. Gastroenterol. Hepatol. 12, 1262–1266 (2014).
  CAS PubMed Google Scholar
• Huang, D. Q. et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase. Clin. Gastroenterol. Hepatol. 20, 1803–1812.e5 (2022).
  CAS PubMed Google Scholar
• Huang, Y. T. et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J. Clin. Oncol. 29, 3643–3650 (2011).
  PubMed PubMed Central Google Scholar
• McMahon, B. J. Natural history of chronic hepatitis B. Clin. Liver Dis. 14, 381–396 (2010).
  PubMed Google Scholar
• World Health Organization. Global Hepatitis Report 2017 (World Health Organization, 2017).
• World Health Organization. Global Health Sector Strategies on, Respectively, HIV, Viral Hepatitis and Sexually Transmitted Infections for the Period 2022–2030 (World Health Organization, 2022).
• Nayagam, S. et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect. Dis. 16, 1399–1408 (2016).
  PubMed Google Scholar
• Blach, S. et al. Evaluation of global progress towards HBV and HCV elimination. J. Hepatol. 77, S230–S231 (2022).
  Google Scholar
• Razavi-Shearer, D. et al. The disease burden of hepatitis B and hepatitis C from 2015 to 2030: the long and winding road [Abstract OS050]. J. Hepatol. 77, S43 (2022).
  Google Scholar
• World Health Organization. Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections 2021. WHO https://www.who.int/publications/i/item/9789240027077 (2021).
• World Health Organization. Hepatitis B. WHO https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (2021).
• Beasley, R. P. et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J. Infect. Dis. 146, 198–204 (1982).
  CAS PubMed Google Scholar
• Chang, K. C. et al. Universal infant hepatitis B virus (HBV) vaccination for 35 years: moving toward the eradication of HBV. J. Infect. Dis. 225, 431–435 (2022).
  CAS PubMed Google Scholar
• Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol. Hepatol. 3, 383–403 (2018).
  Google Scholar
• GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204–1222 (2020).
  Google Scholar
• Schmit, N., Nayagam, S., Thursz, M. R. & Hallett, T. B. The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups. Int. J. Epidemiol. 50, 560–569 (2021).
  PubMed Google Scholar
• de Villiers, M. J. et al. Modelling hepatitis B virus infection and impact of timely birth dose vaccine: a comparison of two simulation models. PLoS ONE 15, e0237525 (2020).
  PubMed PubMed Central Google Scholar
• Simonetti, J. et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 51, 1531–1537 (2010).
  PubMed Google Scholar
• Huang, D. Q. & Lim, S. G. Life after s loss: impact of hepatitis B s antigen loss on future patient outcomes. Clin. Liver Dis. 16, 262–265 (2020).
  CAS Google Scholar
• Wong, D. K. et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 54, 829–836 (2011).
  CAS PubMed Google Scholar
• Covolo, L., Pollicino, T., Raimondo, G. & Donato, F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig. Liver Dis. 45, 238–244 (2013).
  PubMed Google Scholar
• The World Bank. World Bank Country and Lending Groups. The World Bank https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (2022).
• United Nations Conference on Trade and Development. List of Least Developed Countries. UNCTAD https://unctad.org/topic/least-developed-countries/map (2022).
• European Centre for Disease Prevention and Control. Systematic Review on Hepatitis B and C Prevalence in the EU/EEA. ECDC https://www.ecdc.europa.eu/en/publications-data/systematic-review-hepatitis-b-and-c-prevalence-eueea (2016).
• Durro, V. & Qyra, S. Trends in prevalence of hepatitis B virus infection among Albanian blood donors, 1999–2009. Virol. J. 8, 96 (2011).
  PubMed PubMed Central Google Scholar
• Gheorghe, L., Csiki, I. E., Iacob, S. & Gheorghe, C. The prevalence and risk factors of hepatitis B virus infection in an adult population in Romania: a nationwide survey. Eur. J. Gastroenterol. Hepatol. 25, 56–64 (2013).
  PubMed Google Scholar
• Wong, R. J. et al. An updated assessment of chronic hepatitis B prevalence among foreign-born persons living in the United States. Hepatology 74, 607–626 (2021).
  PubMed Google Scholar
• Rossi, C. et al. Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis. PLoS ONE 7, e44611 (2012).
  CAS PubMed PubMed Central Google Scholar
• Ahmad, A. A. et al. Estimating the scale of chronic hepatitis B virus infection among migrants in EU/EEA countries. BMC Infect. Dis. 18, 34 (2018).
  PubMed PubMed Central Google Scholar
• Moutchia, J. et al. Maternal age at first childbirth and geographical variation in hepatitis B virus prevalence in Cameroon: important role of mother-to-child transmission. Clin. Infect. Dis. 74, 836–845 (2022).
  PubMed Google Scholar
• Malabarey, O. T., Balayla, J., Klam, S. L., Shrim, A. & Abenhaim, H. A. Pregnancies in young adolescent mothers: a population-based study on 37 million births. J. Pediatr. Adolesc. Gynecol. 25, 98–102 (2012).
  PubMed Google Scholar
• Lim, J. K. et al. Prevalence of chronic hepatitis B virus infection in the United States. Am. J. Gastroenterol. 115, 1429–1438 (2020).
  PubMed Google Scholar
• Rashti, R. et al. Global prevalence of HCV and/or HBV coinfections among people who inject drugs and female sex workers who live with HIV/AIDS: a systematic review and meta-analysis. Arch. Virol. 165, 1947–1958 (2020).
  CAS PubMed Google Scholar
• Adane, T. & Getawa, S. The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: a systematic review and meta-analysis. PLoS ONE 16, e0251570 (2021).
  CAS PubMed PubMed Central Google Scholar
• Mokaya, J. et al. A blind spot? Confronting the stigma of hepatitis B virus (HBV) infection — a systematic review. Wellcome Open Res. 3, 29 (2018).
  PubMed PubMed Central Google Scholar
• Braveman, P. A., Cubbin, C., Egerter, S., Williams, D. R. & Pamuk, E. Socioeconomic disparities in health in the United States: what the patterns tell us. Am. J. Public Health 100, S186–S196 (2010).
  PubMed PubMed Central Google Scholar
• Wong, G. L. et al. An aging population of chronic hepatitis B with increasing comorbidities: a territory-wide study from 2000 to 2017. Hepatology 71, 444–455 (2020).
  PubMed Google Scholar
• Nguyen, M. H. et al. Advancing age and comorbidity in a US insured population-based cohort of patients with chronic hepatitis B. Hepatology 69, 959–973 (2019).
  PubMed Google Scholar
• Tseng, C. H., Hsu, Y. C., Ho, H. J., Nguyen, M. H. & Wu, C. Y. Increasing age and nonliver comorbidities in patients with chronic hepatitis B in Taiwan: a nationwide population-based analysis. Dig. Dis. 39, 266–274 (2021).
  PubMed Google Scholar
• Hou, J. et al. Shifting demographics and comorbidity burden in adult Chinese urban patients with chronic hepatitis B, 2013 and 2016. J. Comp. Eff. Res. 10, 647–657 (2021).
  PubMed Google Scholar
• Yotsuyanagi, H. et al. Characteristics and healthcare costs in the aging hepatitis B population of Japan: a nationwide real-world analysis. Dig. Dis. 40, 68–77 (2022).
  PubMed Google Scholar
• Sanai, F. M. et al. Greater prevalence of comorbidities with increasing age: cross-sectional analysis of chronic hepatitis B patients in Saudi Arabia. Saudi J. Gastroenterol. 25, 194–200 (2019).
  PubMed PubMed Central Google Scholar
• Oh, H. et al. Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis B. Aliment. Pharmacol. Ther. 52, 371–381 (2020).
  PubMed Google Scholar
• Lok, A. S. et al. Low incidence of adverse outcomes in adults with chronic hepatitis B virus infection in the era of antiviral therapy. Hepatology 73, 2124–2140 (2021).
  CAS PubMed Google Scholar
• Roser, M., Ortiz-Ospina, E. & Ritchie, H. Life expectancy. Our World in Data https://ourworldindata.org/life-expectancy (2019).
• Hsu, Y. C., Tseng, C. H., Huang, Y. T. & Yang, H. I. Application of risk scores for hepatocellular carcinoma in patients with chronic hepatitis B: current status and future perspective. Semin. Liver Dis. 41, 285–297 (2021).
  PubMed Google Scholar
• Hsu, Y. C., Wei, M. T. & Nguyen, M. H. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. Expert Rev. Gastroenterol. Hepatol. 11, 999–1008 (2017).
  CAS PubMed Google Scholar
• Platt, L. et al. Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis. J. Viral Hepat. 27, 294–315 (2020).
  PubMed Google Scholar
• Lin, H. H. et al. Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. Hepatology 61, 1870–1879 (2015).
  CAS PubMed Google Scholar
• Ahmadi Gharaei, H. et al. The global and regional prevalence of hepatitis C and B co-infections among prisoners living with HIV: a systematic review and meta-analysis. Infect. Dis. Poverty 10, 93 (2021).
  PubMed PubMed Central Google Scholar
• Thio, C. L. et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort study (MACS). Lancet 360, 1921–1926 (2002).
  PubMed Google Scholar
• Alfaiate, D., Clement, S., Gomes, D., Goossens, N. & Negro, F. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J. Hepatol. 73, 533–539 (2020).
  PubMed Google Scholar
• European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370–398 (2017).
  Google Scholar
• Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67, 1560–1599 (2018).
  PubMed Google Scholar
• Sarin, S. K. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol. Int. 10, 1–98 (2016).
  CAS PubMed Google Scholar
• Chen, G. et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology 66, 13–26 (2017).
  CAS PubMed Google Scholar
• Yeh, M. L. et al. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. J. Hepatol. 73, 62–71 (2020).
  CAS PubMed Google Scholar
• Sandmann, L. & Cornberg, M. Experimental drugs for the treatment of hepatitis D. J. Exp. Pharmacol. 13, 461–468 (2021).
  PubMed PubMed Central Google Scholar
• Lampertico, P., Roulot, D. & Wedemeyer, H. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies. J. Hepatol. 77, 1422–1430 (2022).
  CAS PubMed Google Scholar
• Zheng, Q. et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment. Pharmacol. Ther. 54, 1100–1109 (2021).
  CAS PubMed Google Scholar
• Le, M. H. et al. 2019 Global NAFLD prevalence: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 20, 2809–2817.e28 (2022).
  PubMed Google Scholar
• Wong, M. C. S. et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat. Rev. Gastroenterol. Hepatol. 16, 57–73 (2019).
  PubMed Google Scholar
• Li, J. et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 4, 389–398 (2019).
  PubMed Google Scholar
• Machado, M. V., Oliveira, A. G. & Cortez-Pinto, H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J. Gastroenterol. Hepatol. 26, 1361–1367 (2011).
  PubMed Google Scholar
• Wong, V. W. et al. Hepatitis B virus infection and fatty liver in the general population. J. Hepatol. 56, 533–540 (2012).
  PubMed Google Scholar
• Hu, D. et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatol. Int. 12, 438–446 (2018).
  PubMed Google Scholar
• Mak, L. Y. et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J. Hepatol. 73, 800–806 (2020).
  CAS PubMed Google Scholar
• Hsu, Y. C. et al. Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B. J. Infect. Dis. 224, 1890–1899 (2021).
  CAS PubMed Google Scholar
• Li, J. et al. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. Liver Int. 40, 1052–1061 (2020).
  CAS PubMed Google Scholar
• Choi, H. S. J. et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology 71, 539–548 (2020).
  CAS PubMed Google Scholar
• van Kleef, L. A. et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 3, 100350 (2021).
  PubMed PubMed Central Google Scholar
• Li, J. et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B. J. Infect. Dis. 224, 294–302 (2021).
  CAS PubMed Google Scholar
• GBD Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol. Hepatol. 7, 796–829 (2022).
  Google Scholar
• Huang, D. Q. et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 34, 969–977.e2 (2022).
  CAS PubMed PubMed Central Google Scholar
• Chang, M. L. & Liaw, Y. F. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J. Hepatol. 61, 1407–1417 (2014).
  PubMed Google Scholar
• Ghany, M. G. et al. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. Lancet Gastroenterol. Hepatol. 5, 406–417 (2020).
  PubMed PubMed Central Google Scholar
• Chen, C. Y. et al. Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan. BMC Gastroenterol. 18, 6 (2018).
  PubMed PubMed Central Google Scholar
• Paul, S. et al. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann. Intern. Med. 164, 30–40 (2016).
  PubMed Google Scholar
• Chen, M. H. et al. Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. J. Infect. Dis. 215, 566–573 (2017).
  CAS PubMed Google Scholar
• Tseng, C. H. et al. Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: a systematic review and meta-analysis. JHEP Rep. 5, 100617 (2023).
  PubMed Google Scholar
• Liu, Y. C., Jeng, W. J., Peng, C. W., Chien, R. N. & Liaw, Y. F. Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies. Liver Int. 42, 551–560 (2022).
  CAS PubMed Google Scholar
• Hsu, Y. C. et al. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. Aliment. Pharmacol. Ther. 49, 107–115 (2019).
  CAS PubMed Google Scholar
• Cacoub, P. & Asselah, T. Hepatitis B virus infection and extra-hepatic manifestations: a systemic disease. Am. J. Gastroenterol. 117, 253–263 (2022).
  CAS PubMed Google Scholar
• Cacoub, P. et al. Hepatitis B virus genotypes and extrahepatic manifestations. J. Hepatol. 43, 764–770 (2005).
  CAS PubMed Google Scholar
• Han, S. H. Extrahepatic manifestations of chronic hepatitis B. Clin. Liver Dis. 8, 403–418 (2004).
  PubMed Google Scholar
• Si, J. et al. Chronic hepatitis B virus infection and total and cause-specific mortality: a prospective cohort study of 0.5 million people. BMJ Open 9, e027696 (2019).
  PubMed PubMed Central Google Scholar
• Chen, Y. C., Su, Y. C., Li, C. Y., Wu, C. P. & Lee, M. S. A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan. Kidney Int. 87, 1030–1038 (2015).
  PubMed Google Scholar
• Song, C. et al. Associations between hepatitis B virus infection and risk of all cancer types. JAMA Netw. Open 2, e195718 (2019).
  PubMed PubMed Central Google Scholar
• Li, M. et al. Hepatitis B virus and risk of non-Hodgkin lymphoma: an updated meta-analysis of 58 studies. J. Viral Hepat. 25, 894–903 (2018).
  CAS PubMed Google Scholar
• Cotler, S. J. et al. Characterizing hepatitis B stigma in Chinese immigrants. J. Viral Hepat. 19, 147–152 (2012).
  CAS PubMed Google Scholar
• Freeland, C. et al. Common concerns, barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study. BMC Public Health 21, 1004 (2021).
  PubMed PubMed Central Google Scholar
• Zhang, M. et al. Assessing health-related quality of life and health utilities in patients with chronic hepatitis B-related diseases in China: a cross-sectional study. BMJ Open 11, e047475 (2021).
  PubMed PubMed Central Google Scholar
• Daida, Y. G. et al. Mental and physical health status among chronic hepatitis B patients. Qual. Life Res. 29, 1567–1577 (2020).
  PubMed PubMed Central Google Scholar
• Chen, P. et al. Health-related quality of life and its influencing factors in patients with hepatitis B: a cross-sectional assessment in Southeastern China. Can. J. Gastroenterol. Hepatol. 2021, 9937591 (2021).
  PubMed PubMed Central Google Scholar
• Weiss, M. G., Ramakrishna, J. & Somma, D. Health-related stigma: rethinking concepts and interventions. Psychol. Health Med. 11, 277–287 (2006).
  PubMed Google Scholar
• Tan, S. H. S., Wang, D., Tan, W. J., Allameen, N. A. & Fong, N. P. Facilitators and barriers of hepatitis B screening and vaccination. Vaccine 38, 5447–5453 (2020).
  PubMed Google Scholar
• Tu, T. Stigma: a major barrier to hepatitis B elimination. Nat. Rev. Gastroenterol. Hepatol. 19, 622 (2022).
  PubMed Google Scholar
• Akazong, W. E. et al. Knowledge, attitude and prevalence of hepatitis B virus among healthcare workers: a cross-sectional, hospital-based study in Bamenda Health District, NWR, Cameroon. BMJ Open 10, e031075 (2020).
  Google Scholar
• Hang Pham, T. T. et al. Knowledge, attitudes and medical practice regarding hepatitis B prevention and management among healthcare workers in Northern Vietnam. PLoS ONE 14, e0223733 (2019).
  CAS PubMed PubMed Central Google Scholar
• Cama, E., Brener, L., Broady, T., Hopwood, M. & Treloar, C. Australian health and medical workers’ concerns around providing care to people living with hepatitis B. Health Soc. Care Community 29, e431–e439 (2021).
  PubMed Google Scholar
• Smith-Palmer, J. et al. Impact of stigma on people living with chronic hepatitis B. Patient Relat. Outcome Meas. 11, 95–107 (2020).
  PubMed PubMed Central Google Scholar
• Lok, A. S. & McMahon, B. J. Chronic hepatitis B. Hepatology 45, 507–539 (2007).
  CAS PubMed Google Scholar
• Mason, A. L., Xu, L., Guo, L., Kuhns, M. & Perrillo, R. P. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 27, 1736–1742 (1998).
  CAS PubMed Google Scholar
• Rehermann, B., Ferrari, C., Pasquinelli, C. & Chisari, F. V. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2, 1104–1108 (1996).
  CAS PubMed Google Scholar
• Raimondo, G. et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J. Hepatol. 71, 397–408 (2019).
  PubMed Google Scholar
• Hsu, C. et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 59, 2092–2100 (2014).
  CAS PubMed Google Scholar
• Yip, T. C. et al. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J. Hepatol. 67, 902–908 (2017).
  CAS PubMed Google Scholar
• Wong, D. K. et al. Among patients with undetectable hepatitis B surface antigen and hepatocellular carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis. Clin. Gastroenterol. Hepatol. 18, 449–456 (2020).
  CAS PubMed Google Scholar
• Candotti, D., Assennato, S. M., Laperche, S., Allain, J. P. & Levicnik-Stezinar, S. Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. Gut 68, 313–321 (2019).
  CAS PubMed Google Scholar
• Ji, D. Z. et al. Global prevalence of occult hepatitis B: a systematic review and meta-analysis. J. Viral Hepat. 29, 317–329 (2022).
  PubMed Google Scholar
• Eltom, K., Albeely, A., El Hussein, A. R. M., Elkhidir, I. M. & Enan, K. Occult hepatitis B virus infection in Sudan: a systematic review and meta-analysis. JGH Open 4, 800–807 (2020).
  PubMed PubMed Central Google Scholar
• Lee, C., Gong, Y., Brok, J., Boxall, E. H. & Gluud, C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD004790.pub2 (2006).
  Article PubMed Google Scholar
• Pan, C. Q. et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N. Engl. J. Med. 374, 2324–2334 (2016).
  CAS PubMed Google Scholar
• Funk, A. L. et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect. Dis. 21, 70–84 (2021).
  CAS PubMed Google Scholar
• Cox, A. L. et al. Progress towards elimination goals for viral hepatitis. Nat. Rev. Gastroenterol. Hepatol. 17, 533–542 (2020).
  PubMed PubMed Central Google Scholar
• World Health Organization. Hepatitis B Vaccination Coverage. WHO https://immunizationdata.who.int/pages/coverage/HEPB.html?CODE=Global&group=who_regions&antigen=hepb_bd+hepb3&year_=_ (2022).
• Marion, S. A., Tomm Pastore, M., Pi, D. W. & Mathias, R. G. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am. J. Epidemiol. 140, 734–746 (1994).
  CAS PubMed Google Scholar
• Cui, F. et al. Factors associated with effectiveness of the first dose of hepatitis B vaccine in China: 1992–2005. Vaccine 28, 5973–5978 (2010).
  PubMed Google Scholar
• Allison, R. D., Patel, M. K. & Tohme, R. A. Hepatitis B vaccine birth dose coverage correlates worldwide with rates of institutional deliveries and skilled attendance at birth. Vaccine 35, 4094–4098 (2017).
  PubMed PubMed Central Google Scholar
• Moturi, E. et al. Implementing a birth dose of hepatitis B vaccine in Africa: findings from assessments in 5 countries. J. Immunol. Sci. Suppl. 5, 31–40 (2018).
  Google Scholar
• Tanaka, J. et al. Countermeasures against viral hepatitis B and C in Japan: an epidemiological point of view. Hepatol. Res. 49, 990–1002 (2019).
  PubMed PubMed Central Google Scholar
• Machaira, M., Papaevangelou, V., Vouloumanou, E. K., Tansarli, G. S. & Falagas, M. E. Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis. J. Antimicrob. Chemother. 70, 396–404 (2015).
  CAS PubMed Google Scholar
• Chen, H. L. et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 142, 773–781.e2 (2012).
  PubMed Google Scholar
• Shimakawa, Y. et al. Residual risk of mother-to-child transmission of hepatitis B virus infection despite timely birth-dose vaccination in Cameroon (ANRS 12303): a single-centre, longitudinal observational study. Lancet Glob. Health 10, e521–e529 (2022).
  CAS PubMed Google Scholar
• World Health Organization. Prevention of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy (World Health Organization, 2020).
• Kumar, M. et al. Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy. Hepatol. Int. 16, 211–253 (2022).
  PubMed Google Scholar
• Murthy, N. et al. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older — United States, 2022. MMWR Morb. Mortal. Wkly Rep. 71, 229–233 (2022).
  CAS PubMed PubMed Central Google Scholar
• Vesikari, T. et al. Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine: a phase 3 randomized clinical trial. JAMA Netw. Open 4, e2128652 (2021).
  PubMed PubMed Central Google Scholar
• Diaz-Mitoma, F., Popovic, V. & Spaans, J. N. Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac(R), compared with Engerix-B(R) in healthy Asian adults: a phase 3 randomized clinical trial. Vaccine 39, 3892–3899 (2021).
  CAS PubMed Google Scholar
• Yeo, Y. H., Le, M. H., Chang, E. T., Henry, L. & Nguyen, M. H. Prevalence of undetectable vaccine-induced immunity against hepatitis B virus in US adults at high risk for infection. Hepatology 69, 1385–1397 (2019).
  CAS PubMed Google Scholar
• Schillie, S. et al. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm. Rep. 67, 1–31 (2018).
  PubMed PubMed Central Google Scholar
• Sinn, D. H. et al. Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study. BMC Cancer 19, 286 (2019).
  PubMed PubMed Central Google Scholar
• Nhlane, R. et al. Late presentation of hepatocellular carcinoma highlights the need for a public health programme to eliminate hepatitis B. Lancet 398, 2288 (2021).
  PubMed Google Scholar
• Beguelin, C., Fall, F., Seydi, M. & Wandeler, G. The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa. Expert Rev. Gastroenterol. Hepatol. 12, 537–546 (2018).
  CAS PubMed Google Scholar
• Ogawa, E. et al. Diagnosis rates of chronic hepatitis B in privately insured patients in the United States. JAMA Netw. Open 3, e201844 (2020).
  PubMed PubMed Central Google Scholar
• Li, M. et al. Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China. Lancet Reg. Health West Pac. 16, 100249 (2021).
  PubMed PubMed Central Google Scholar
• Lok, A. S. et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology 63, 284–306 (2016).
  CAS PubMed Google Scholar
• World Health Organization. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. WHO https://www.who.int/publications/i/item/9789241549059 (2015).
• Tan, M. et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 6, 106–119 (2021).
  PubMed Google Scholar
• Cheng, H. et al. Uptake of hepatitis B antiviral treatment: a panel data analysis of 31 provinces in China (2013–2020). Liver Int. 42, 1762–1769 (2022).
  PubMed Google Scholar
• Aberra, H. et al. The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia. J. Hepatol. 70, 1065–1071 (2019).
  PubMed Google Scholar
• Ye, Q. et al. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. J. Hepatol. 76, 63–74 (2022).
  CAS PubMed Google Scholar
• Sinn, D. H., Kim, S. E., Kim, B. K., Kim, J. H. & Choi, M. S. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. J. Viral Hepat. 26, 1465–1472 (2019).
  CAS PubMed Google Scholar
• Liu, M. et al. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. Hepatol. Int. 15, 71–81 (2021).
  PubMed Google Scholar
• Park, J. et al. Progression rates by age, sex, treatment, and disease activity by AASLD and EASL criteria: data for precision medicine. Clin. Gastroenterol. Hepatol. 20, 874–885.e4 (2022).
  PubMed Google Scholar
• Wu, C. Y. et al. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut 65, 693–701 (2016).
  PubMed Google Scholar
• Tran, S., Jeong, D., Henry, L., Cheung, R. C. & Nguyen, M. H. Initial evaluation, long-term monitoring, and hepatocellular carcinoma surveillance of chronic hepatitis B in routine practice: a nationwide US study. Am. J. Gastroenterol. 116, 1885–1895 (2021).
  PubMed Google Scholar
• Wang, B., Mufti, G. & Agarwal, K. Reactivation of hepatitis B virus infection in patients with hematologic disorders. Haematologica 104, 435–443 (2019).
  CAS PubMed PubMed Central Google Scholar
• Hsu, P. I. et al. Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic area. Hepatology 62, 387–396 (2015).
  PubMed Google Scholar
• Hwang, J. P., Ferrajoli, A. & Lok, A. S. Hepatitis B reactivation after chemoimmunotherapy: screen before treatment. Lancet 397, 510 (2021).
  PubMed PubMed Central Google Scholar
• Ujiie, M., Sasaki, K., Yoshikawa, N., Enami, T. & Shobayashi, T. Introduction of a hepatitis B vaccine into the national routine immunisation programme of Japan. Lancet Infect. Dis. 16, 1325 (2016).
  PubMed Google Scholar
• Seaman, C. P. et al. Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study. Lancet Glob. Health 8, e931–e941 (2020).
  PubMed Google Scholar
• Njai, H. F. et al. Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa. J. Clin. Microbiol. 53, 1156–1163 (2015).
  PubMed PubMed Central Google Scholar
• Shimakawa, Y., Seck, A., Nayagam, S., Toure-Kane, C. & Lemoine, M. Screening strategies to prevent mother-to-child transmission of hepatitis B in sub-Saharan Africa. Lancet Gastroenterol. Hepatol. 3, 222–223 (2018).
  PubMed Google Scholar
• Mokaya, J. et al. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa. BMC Public Health 19, 829 (2019).
  PubMed PubMed Central Google Scholar
• Weng, M. K. Universal Adult Hepatitis B Vaccination: Work Group Considerations. CDC https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-2-3/02-HepWG-weng-508.pdf (2021).
• Toy, M. et al. Cost-effectiveness of 1-time universal screening for chronic hepatitis B infection in adults in the United States. Clin. Infect. Dis. 74, 210–217 (2022).
  PubMed Google Scholar
• Su, S. et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. Lancet Glob. Health 10, e278–e287 (2022).
  CAS PubMed PubMed Central Google Scholar
• Hall, E. W. et al. Assessing the cost-utility of universal hepatitis B vaccination among adults. J. Infect. Dis. https://doi.org/10.1093/infdis/jiac088 (2022).
  Article PubMed PubMed Central Google Scholar
• Spearman, C. W. et al. Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. Lancet Gastroenterol. Hepatol. 2, 900–909 (2017).
  PubMed Google Scholar
• McNaughton, A. L. et al. Hepatitis B virus seroepidemiology data for Africa: modelling intervention strategies based on a systematic review and meta-analysis. PLoS Med. 17, e1003068 (2020).
  PubMed PubMed Central Google Scholar
• Ramrakhiani, N. S. et al. Optimizing hepatitis B virus screening in the United States using a simple demographics-based model. Hepatology 75, 430–437 (2022).
  PubMed Google Scholar
• Chan, A. H. Y. et al. Effect of electronic adherence monitoring on adherence and outcomes in chronic conditions: a systematic review and meta-analysis. PLoS ONE 17, e0265715 (2022).
  CAS PubMed PubMed Central Google Scholar
• Shimakawa, Y. et al. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. J. Hepatol. 69, 776–784 (2018).
  PubMed Google Scholar
• Vu Hai, V. et al. Assessment and simplification of treatment eligibility among patients with chronic hepatitis B infection in Vietnam. Clin. Infect. Dis. 73, e1072–e1077 (2021).
  CAS Google Scholar
• Hsu, Y. C. et al. Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial. Lancet Infect. Dis. 21, 823–833 (2021).
  CAS PubMed Google Scholar
• Choi, G. H., Kim, G. A., Choi, J., Han, S. & Lim, Y. S. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment. Pharmacol. Ther. 50, 215–226 (2019).
  CAS PubMed Google Scholar
• Hoang, J. K. et al. Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis. Medicine 95, e4433 (2016).
  PubMed PubMed Central Google Scholar
• Hsu, Y. C. et al. Inhibition of viral replication reduces transcriptionally active distinct hepatitis B virus integrations with implications on host gene dysregulation. Gastroenterology 162, 1160–1170.e1 (2022).
  CAS PubMed Google Scholar
• Chow, N. et al. Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciac383 (2022).
  Article PubMed PubMed Central Google Scholar
• Lim, Y. S. et al. Impact of expanding hepatitis B treatment guidelines: a modelling and economic impact analysis. Aliment. Pharmacol. Ther. 56, 519–528 (2022).
  CAS PubMed Google Scholar
• Younossi, Z. M. et al. Effects of treatment of chronic hepatitis B virus infection on patient-reported outcomes. Clin. Gastroenterol. Hepatol. 16, 1641–1649.e6 (2018).
  PubMed Google Scholar
• Wong, G. L. et al. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: a cohort study of 53,500 subjects. Hepatology 62, 684–693 (2015).
  CAS PubMed Google Scholar
• Revill, P., Testoni, B., Locarnini, S. & Zoulim, F. Global strategies are required to cure and eliminate HBV infection. Nat. Rev. Gastroenterol. Hepatol. 13, 239–248 (2016).
  CAS PubMed Google Scholar